Effects of Wheat Bran Extract Containing Arabinoxylan Oligosaccharides on Gastrointestinal Parameters in Healthy Preadolescent Children
Isabelle E.J.A. François
FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, Leuven
Search for more papers by this authorOlivier Lescroart
FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, Leuven
Search for more papers by this authorWim S. Veraverbeke
FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, Leuven
Search for more papers by this authorMassimo Marzorati
Laboratory of Microbial Ecology and Technology (LabMet), Ghent University, Gent
Search for more papers by this authorSam Possemiers
Laboratory of Microbial Ecology and Technology (LabMet), Ghent University, Gent
Search for more papers by this authorHenrike Hamer
Translational Research for Gastrointestinal Disorders (Targid) and Leuven Food Science and Nutrition Research Centre (LFoRCe), University Hospitals UZ Leuven, Leuven, Belgium
Search for more papers by this authorKaren Windey
Translational Research for Gastrointestinal Disorders (Targid) and Leuven Food Science and Nutrition Research Centre (LFoRCe), University Hospitals UZ Leuven, Leuven, Belgium
Search for more papers by this authorGjalt W. Welling
Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Search for more papers by this authorJan A. Delcour
Laboratory of Food Chemistry and Biochemistry & Leuven Food Science and Nutrition Research Centre (LFoRCe), KU Leuven, Leuven, Belgium
Search for more papers by this authorChristophe M. Courtin
Laboratory of Food Chemistry and Biochemistry & Leuven Food Science and Nutrition Research Centre (LFoRCe), KU Leuven, Leuven, Belgium
Search for more papers by this authorKristin Verbeke
Translational Research for Gastrointestinal Disorders (Targid) and Leuven Food Science and Nutrition Research Centre (LFoRCe), University Hospitals UZ Leuven, Leuven, Belgium
Search for more papers by this authorCorresponding Author
Willem F. Broekaert
FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, Leuven
Address correspondence and reprint requests to Willem F. Broekaert, PhD, FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, B-3001 Leuven, Belgium (e-mail: [email protected]).Search for more papers by this authorIsabelle E.J.A. François
FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, Leuven
Search for more papers by this authorOlivier Lescroart
FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, Leuven
Search for more papers by this authorWim S. Veraverbeke
FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, Leuven
Search for more papers by this authorMassimo Marzorati
Laboratory of Microbial Ecology and Technology (LabMet), Ghent University, Gent
Search for more papers by this authorSam Possemiers
Laboratory of Microbial Ecology and Technology (LabMet), Ghent University, Gent
Search for more papers by this authorHenrike Hamer
Translational Research for Gastrointestinal Disorders (Targid) and Leuven Food Science and Nutrition Research Centre (LFoRCe), University Hospitals UZ Leuven, Leuven, Belgium
Search for more papers by this authorKaren Windey
Translational Research for Gastrointestinal Disorders (Targid) and Leuven Food Science and Nutrition Research Centre (LFoRCe), University Hospitals UZ Leuven, Leuven, Belgium
Search for more papers by this authorGjalt W. Welling
Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Search for more papers by this authorJan A. Delcour
Laboratory of Food Chemistry and Biochemistry & Leuven Food Science and Nutrition Research Centre (LFoRCe), KU Leuven, Leuven, Belgium
Search for more papers by this authorChristophe M. Courtin
Laboratory of Food Chemistry and Biochemistry & Leuven Food Science and Nutrition Research Centre (LFoRCe), KU Leuven, Leuven, Belgium
Search for more papers by this authorKristin Verbeke
Translational Research for Gastrointestinal Disorders (Targid) and Leuven Food Science and Nutrition Research Centre (LFoRCe), University Hospitals UZ Leuven, Leuven, Belgium
Search for more papers by this authorCorresponding Author
Willem F. Broekaert
FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, Leuven
Address correspondence and reprint requests to Willem F. Broekaert, PhD, FUGEIA NV, Arenberg Science Park, Gaston Geenslaan 1, B-3001 Leuven, Belgium (e-mail: [email protected]).Search for more papers by this authorwww.clinicaltrials.gov registration number: NCT01001949.
I.E.J.A.F., O.L., W.S.V., and W.F.B. were, during the course of the study, employed by FUGEIA NV, which manufactures the wheat bran extract product, and is the sole sponsor source of funding for the studies described herein. The other authors report no conflicts of interest.
ABSTRACT
Objectives:
We assessed whether wheat bran extract (WBE) containing arabinoxylan-oligosaccharides (AXOS) elicited a prebiotic effect and modulated gastrointestinal (GI) parameters in healthy preadolescent children upon consumption in a beverage.
Methods:
This double-blind randomized placebo-controlled crossover trial evaluated the effects of consuming WBE at 0 (control) or 5.0 g/day for 3 weeks in 29 healthy children (8–12 years). Fecal levels of microbiota, short-chain fatty acids, branched-chain fatty acids, ammonia, moisture, and fecal pH were assessed at the end of each treatment and at the end of a 1-week run-in (RI) period. In addition, the subjects completed questionnaires scoring distress severity of 3 surveyed GI symptoms. Finally, subjects recorded defecation frequency and stool consistency.
Results:
Nominal fecal bifidobacteria levels tended to increase after 5 g/day WBE consumption (P = 0.069), whereas bifidobacteria expressed as percentage of total fecal microbiota was significantly higher upon 5 g/day WBE intake (P = 0.002). Additionally, 5 g/day WBE intake induced a significant decrease in fecal content of isobutyric acid and isovaleric acid (P < 0.01), markers of protein fermentation. WBE intake did not cause a change in distress severity of the 3 surveyed GI symptoms (flatulence, abdominal pain/cramps, and urge to vomit) (P > 0.1).
Conclusions:
WBE is well tolerated at doses up to 5 g/day in healthy preadolescent children. In addition, the intake of 5 g/day exerts beneficial effects on gut parameters, in particular an increase in fecal bifidobacteria levels relative to total fecal microbiota, and reduction of colonic protein fermentation.
REFERENCES
- 1Broekaert WF, Courtin CM, Verbeke K, et al. Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides and xylo-oligosaccharides. Crit Rev Food Sci Nutr 2011; 51: 178–194.
- 2Femia AP, Salvadori M, Broekaert WF, et al. Arabinoxylan oligosaccharides (AXOS) reduce preneoplastic lesions in the colon of rats treated with 1,2-dimethylhydrazine (DMH). Eur J Nutr 2010; 49: 127–132.
- 3Yamada H, Itoh K, Morishita Y, et al. Structure and properties of oligosaccharides from wheat bran. Cereal Food World 1993; 38: 490–492.
- 4Courtin CM, Swennen K, Broekaert WF, et al. Dietary inclusion of wheat bran arabinoxylooligosaccharides has beneficial nutritional effects on chickens. Cereal Chem 2008; 85: 607–613.
- 5Courtin CM, Swennen K, Broekaert WF, et al. Effects of dietary inclusion of xylooligosaccharides, arabinoxylooligosaccharides and soluble arabinoxylan on the microbial composition of caecal contents of chickens. J Sci Food Agric 2008; 88: 2517–2522.
- 6Van Craeyveld V, Swennen K, Dornez E, et al. Structurally different wheat-derived arabinoxylooligosaccharides have different prebiotic and fermentation properties in rats. J Nutr 2008; 138: 2348–2355.
- 7Cloetens L, Broekaert WF, Delaedt Y, et al. Tolerance of arabinoxylan-oligosaccharides and their prebiotic activity in healthy subjects: a randomised, placebo-controlled cross-over study. Br J Nutr 2010; 103: 703–713.
- 8François IEJA, Lescroart O, Veraverbeke WS, et al. Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: a double-blind, randomized, placebo-controlled, crossover trial. Br J Nutr 2012; 108: 2229–2242.
- 9Maki KC, Gibson GR, Dickmann RS, et al. Digestive and physiological effects of a wheat bran extract, arabino-xylan-oligosaccharide, in breakfast cereal. Nutrition 2012; 28: 1115–1121.
- 10Hamer HM, De Preter V, Cloetens L, et al. A dietary intervention with arabinoxylan oligosaccharides reduces colonic protein fermentation in healthy subjects: results from faecal metabolite fingerprint analysis. Gastroenterology 2010; 138 (S1): 616.
- 11Hughes R, Magee EA, Bingham S. Protein degradation in the large intestine: relevance to colorectal cancer. Curr Issues Intest Microbiol 2000; 1: 51–58.
- 12Bammens B, Evenepoel P, Keuleers H, et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081–1087.
- 13Bone E, Tamm A, Hill M. Production of urinary phenols by gut bacteria and their possible role in causation of large bowel cancer. Am J Clin Nutr 1976; 29: 1448–1454.
- 14De Graaf AA, Venema K. Gaining insight into microbial physiology in the large intestine: a special role for stable isotopes. Adv Microb Physiol 2008; 53: 73–168.
- 15Attene-Ramos MS, Wagner ED, Plewa MJ, et al. Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res 2006; 4: 9–14.
- 16Bartram HP, Scheppach W, Schmid H, et al. Proliferation of human colonic mucosa as an intermediate biomarker of carcinogenesis: effects of butyrate, deoxycholate, calcium, ammonia, and pH. Cancer Res 1993; 53: 3283–3288.
- 17Leschelle X, Robert V, Delpal S, et al. Isolation of pig crypts for cytotoxic assay of luminal compounds: effects of hydrogen sulfide, ammonia, and deoxycholic acid. Cell Biol Toxicol 2002; 18: 193–203.
- 18Andriamihaja M, Davila AM, Eklou-Lawson M, et al. Colon luminal content and epithelial cell morphology are markedly modified in rats fed with a high-protein diet. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1030–G1037.
- 19Toden S, Bird AR, Topping DL, et al. Resistant starch attenuates colonic DNA damage induced by higher dietary protein in rats. Nutr Cancer 2005; 51: 45–51.
- 20Paliy O, Kenche H, Abernathy F, et al. High throughput quantitative analysis of the human intestinal microbiota with a phylogenetic microarray. Appl Environ Microb 2009; 75: 3572–3579.
- 21Agans R, Rigsbee L, Kenche H, et al. Distal gut microbiota of adolescent children is different from that of adults. FEMS Microbiol Ecol 2011; 77: 404–412.
- 22Swennen K, Courtin CM, Lindemans GCJE, et al. Large scale production and characterisation of wheat bran arabinoxylooligosaccharides. J Sci Food Agric 2006; 86: 1722–1731.
- 23Van de Wiele T, Boon N, Possemiers S, et al. Prebiotic effects of chicory inulin in the simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol 2004; 51: 143–153.
- 24Yap WKW, Mohamed S, Jamal MH, et al. Changes in infants faecal characteristics and microbiota by inulin supplementation. J Clin Biochem Nutr 2008; 43: 159–166.
- 25Bremner JM, Keeney RD. Steam distillation methods for determination of ammonium, nitrate and nitrite. Anal Chem Acta 1965; 32: 485–495.
- 26Riegler G, Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Techn Coloproct 2001; 5: 163–164.
- 27Maki KC, Carson ML, Miller MP, et al. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia. Eur J Clin Nutr 2009; 63: 1001–1007.
- 28Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York: Springer-Verlag; 2004.
- 29 Deleted in proof.
- 30Shapiro SS, Wilk MB. An analysis of variance test for normality [complete samples]. Biometrika 1965; 52: 591–611.
- 31Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 1981; 35: 124–129.
- 32Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biometrical J 2008; 50: 346–363.
- 33Sidak Z. Rectangular confidence region for the means of multivariate normal distributions. J Am Stat Assoc 1967; 62: 626–633.
- 34Molenberghs G, Verbeke G. Models for Discrete Longitudinal Data. New York: Springer; 2005.
- 35Cloetens L. In Vivo Evaluation of the Gastrointestinal Effects of Arabinoxylan-Oligosaccharides in Healthy Subjects [PhD thesis]. Leuven, Belgium: University of Leuven; 2009.
- 36Taipale T, Pienihäkkinen K, Isolauri E, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr 2011; 105: 409–416.
- 37O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541–551.
- 38Guglielmetti S, Mora D, Gschwender M, et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 1123–1132.
- 39Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, et al. Probiotic mechanisms of action. Ann Nutr Metab 2012; 61: 160–174.
- 40Smith EA, Macfarlane GT. Dissimilatory amino acid metabolism in human colonic bacteria. Anaerobe 1997; 3: 327–337.
- 41Geypens B, Claus D, Evenepoel P, et al. Influence of dietary protein supplements on the fermentation of bacterial metabolites in the colon. Gut 1997; 41: 70–76.
- 42Cloetens L, De Preter V, Swennen K, et al. Dose-response effect of arabinoxylooligosaccharides on gastrointestinal motility and on colonic bacterial metabolism in healthy volunteers. J Am Col Nutr 2008; 27: 512–518.
- 43De Preter V, Falony G, Windey K, et al. The prebiotic, oligofructose-enriched inulin modulates the faecal metabolite profile: an in vitro analysis. Mol Nutr Food Res 2010; 54: 1791–1801.
- 44Belenguer A, Duncan S, Holtrop G, et al. Quantitative analysis of microbial metabolism in the human large intestine. Curr Nutr Food Sci 2008; 4: 109–126.
- 45Grabitske HA, Slavin JL. Gastrointestinal effects of low-digestible carbohydrates. Crit Rev Food Sci Nutr 2009; 49: 327–360.
- 46Slavin J, Feirtag J. Chicory inulin does not increase stool weight or speed up intestinal transit time in healthy male subjects. Food Funct 2011; 2: 72–76.
- 47Kruse HP, Kleessen B, Blaut M. Effects of inulin on faecal bifidobacteria in human subjects. Br J Nutr 1999; 82: 375–382.
- 48Bouhnik Y, Raskine L, Champion K, et al. Prolonged administration of low-dose inulin stimulates the growth of bifidobacteria in humans. Nutr Res 2007; 27: 187–193.
- 49Bonnema AL, Kolberg LW, Thomas W, et al. Gastrointestinal tolerance of chicory inulin products. J Am Diet Assoc 2010; 110: 865–868.
- 50Wilson TA, Adolph AL, Butte NF. Nutrient adequacy and diet quality in non-overweight and overweight Hispanic children of low socioeconomic status: the Viva la Familia Study. J Am Diet Assoc 2009; 109: 1012–1021.
Citing Literature
